ANEW Medical Partners With Japan's Okinawa Research Center to Combat Age-Related Diseases
ANEW Medical Partners With Japan's Okinawa Research Center to Combat Age-Related Diseases
ANEW MEDICAL, INC. (NASDAQ:WENA), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics, announces a strategic partnership with Drs. Makoto Suzuki, Craig and Bradley Willcox, Richard Allsopp, and Michio Shimabukuro of Japan's Okinawa Research Center for Longevity Science (ORCLS) for the research and development of ANEW's patented Klotho gene therapy in enhancing longevity and reducing age-related diseases.
ANEW医疗公司（NASDAQ：WENA）是一家生物制药公司，专注于开发用于神经和年龄相关疾病的治疗的新型疾病修正治疗及特殊诊断技术的研究。宣布与日本沖繩長壽科學研究中心的鈴木誠、Craig and Bradley Willcox、Richard Allsopp和島袋道雄博士的战略合作，以研究和开发ANEW的Klotho基因疗法，以提高寿命并减少年龄相关疾病。
'Blue Zones', as coined by National Geographic explorer and journalist Dan Buettner, are located in Ikaria, Greece; the Ogliastra Region of Sardinia; the Nicoya Peninsula in Costa Rica; and Loma Linda, California.
'蓝地区，由国家地理探险家和记者丹·布特纳（Dan Buettner）所起的名字，位于希腊伊卡利亚，萨尔代尼亚的Ogliastra地区，哥斯达黎加的尼科亚半岛和加州洛马林达。沖繩，最初的“蓝地区”，已经成为ORCLS近五十年来重大研究的焦点，导致发现了其他“长寿热点” - 遍布全球。这些区域以高浓度的寿命异常长的人群为特征，同时保持良好健康状况。初步数据表明人的Klotho基因及其分泌的alpha-Klotho蛋白同工异构体可能有助于延长寿命并提供对神经退行性疾病的保护，例如肌萎缩性侧索硬化症（ALS）、阿尔茨海默病（AD）和帕金森病（PD）。显然，冲绳人在全球AD的患病率中居低位。
Okinawa, the original 'Blue Zone', has been the focus of nearly five decades of groundbreaking research by ORCLS, leading to the discovery of other "longevity hotspots" - across the world. These areas are characterized by high concentrations of people who live to exceptional ages, while maintaining good health. Preliminary data suggests that the alpha-Klotho version of the human Klotho gene and its secreted alpha-Klotho protein isoform, may contribute to longevity and provide protection against neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD) and Parkinson's Disease (PD). Remarkably, Okinawans have among the lowest prevalence rates of AD globally.
原始的“蓝地区”蓝区已成为ORCLS近五十年来重大研究的焦点导致发现了其他“长寿热点”，这些区域以高浓度的寿命异常长的人群为特征同时保持良好健康状况。人α-Klotho版本的Klotho基因和其分泌的alpha-Klotho蛋白同工异构体，可能有助于延长寿命并对抗神经退行性疾病，例如肌萎缩性侧索硬化症（ALS）、阿尔茨海默病（AD）和帕金森病（PD）。α-KlothoKlotho显然，冲绳人在全球AD的患病率中居低位。ANEW的任务是在高度未满足的医疗需求领域提供转化性蛋白质、细胞和基因治疗，特别针对高度普遍的神经退行性疾病和年龄相关疾病，包括ALS、AD和PD。与ORCLS的合作是ANEW在日本沖繩进行的研究项目的一部分，该项目因其相对较高的极长寿命的人数而闻名，许多人都活到了100岁以上。
ANEW's mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders including ALS, AD and PD. The collaboration with ORCLS is part of ANEW's research program on the extended life expectancy in Okinawa, Japan, which is renowned for its comparatively high number of people who live extremely long and healthy lives, many reaching 100 years and more.
ANEW正在开发一系列针对Klotho基因的细胞和基因治疗新药组合，以潜在治疗令人沮丧的神经退行性疾病。该公司在主要市场拥有新颖的知识产权组合并正在推进临床发展。
ANEW is developing a groundbreaking portfolio of cell and gene-based therapeutics targeting the Klotho gene for potential treatment of debilitating neurodegenerative diseases. The Company holds a portfolio of novel intellectual property in major markets and is advancing clinical development.
对Klotho基因的革命性组合细胞和基因治疗的开发使ANEW能够获得肺病与保健市场领先者的地位，并为患者提供前所未有的生命缓解。Klotho公司拥有新颖的在主要市场上的知识产权组合并正在推进临床发展。